Theravance Biopharma US Inc

Theravance Biopharma US Inc. is a company based in South San Francisco, California. Established in 2014 as a spin-off of Theravance, Inc., the company employs 415 people and generates approximately $50 million in annual revenue. Theravance Biopharma focuses on developing innovative treatments for specialty respiratory and neurological diseases. Their FDA-approved product, YUPELRI® (revefenacin), is an inhalation solution used to maintain the health of patients with chronic obstructive pulmonary disease (COPD). The company also has a pipeline of internally discovered programs aimed at addressing critical unmet needs in the medical field. Dedicated to delivering medicines that improve the lives of patients and their caregivers, Theravance Biopharma emphasizes a collaborative and innovative work environment. They actively seek creative problem-solvers who are passionate about applying their expertise to discover novel therapies. For those interested in learning more about Theravance Biopharma, the company website is www.theravance.com. They can also be found on Twitter at @TheravanceBio, with guidelines for social media engagement available at www.theravance.com/social-media-guidelines.